Clinical outcomes of recommended active pharmacotherapy agents from NICE guideline for post-traumatic stress disorder: Network meta-analysis.
Prog Neuropsychopharmacol Biol Psychiatry
; 125: 110754, 2023 07 13.
Article
em En
| MEDLINE
| ID: mdl-36934999
ABSTRACT
BACKGROUND:
Post-traumatic stress disorder (PTSD) is a mental disorder that can emerge after an individual experiences a traumatic event such as physical abuse, sexual/relationship violence, combat exposure, witnessing death, or serious injury. This study aimed to identify the most suitable drugs for the management of PTSD based on a network meta-analysis (NMA).METHODS:
Six databases (Ovid Medline, EMBase, CENTRAL, PsycINFO, Ovid Health and Psychosocial Instruments, and Web of Science) were searched from inception to September 6, 2022.RESULTS:
Thirty articles with a total of 5170 participants were included. Compared with placebo, active drugs including olanzapine (SMD = -0.66, 95% CI -1.19 to -0.13), risperidone (SMD = -0.23, 95% CI -0.42 to -0.03), quetiapine (SMD = -0.49, 95% CI -0.93 to -0.04), venlafaxine (SMD = -0.29, 95% CI -0.42 to -0.16), sertraline (SMD = -0.23, 95% CI -0.34 to -0.11), paroxetine (SMD = -0.48, 95% CI -0.60 to -0.36) and fluoxetine (SMD = -0.27, 95% CI -0.42 to -0.12), significantly reduced the total clinician-administered PTSD scale score.CONCLUSION:
The results of this study support the use of paroxetine, venlafaxine, and quetiapine as first-line treatment for PTSD. In addition, quetiapine is recommended for patients with PTSD affected by symptoms of hyperarousal and re-experience disorder. Clinicians should prescribe medications based on the severity of PTSD symptoms and other conditions to develop the best treatment strategy for this patient population.Palavras-chave
Texto completo:
1
Bases de dados:
MEDLINE
Assunto principal:
Transtornos de Estresse Pós-Traumáticos
/
Terapia Cognitivo-Comportamental
Tipo de estudo:
Clinical_trials
/
Diagnostic_studies
/
Guideline
/
Prognostic_studies
/
Systematic_reviews
Limite:
Humans
Idioma:
En
Revista:
Prog Neuropsychopharmacol Biol Psychiatry
Ano de publicação:
2023
Tipo de documento:
Article
País de afiliação:
China